Physician profile
Robert Taglia
NPI 1184624165
$6,930.92
in general payments reported to CMS, 2019-2025
26 companies · $896 in 2025
The $896 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,784 · 2020: $625 · 2021: $614 · 2022: $888 · 2023: $405 · 2024: $719 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,940.76 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $983.38 | 2019-2025 | Breztri |
| Glaxosmithkline, LLC. | $761.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $738.40 | 2021-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.95 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $432.47 | 2019-2025 | Evenity |
| Gilead Sciences, INC. | $245.73 | 2019 | |
| Lilly USA, LLC | $245.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $163.07 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $134.73 | 2019 | |
| Medtronic USA, INC. | $124.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.83 | 2019 | |
| Horizon Therapeutics Plc | $56.52 | 2020-2021 | |
| Pfizer INC. | $52.50 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $36.69 | 2025 | Eliquis, Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $32.43 | 2019-2020 | |
| Lundbeck LLC | $29.49 | 2024 | Vyepti |
| Phathom Pharmaceuticals, INC. | $29.03 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $28.53 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $23.77 | 2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $22.21 | 2023 | Horizant |
| Ucb, INC. | $18.90 | 2025 | Bimzelx |
| Takeda Pharmaceuticals U.S.A., INC. | $15.78 | 2025 | Entyvio |
| Kowa Pharmaceuticals America, INC. | $15.23 | 2021 | |
| Abiomed | $14.41 | 2025 | |
| Paratek Pharmaceuticals, INC. | $13.15 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Taglia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.